Table 5. Summary ORs and 95% CIs of HOTAIR rs1899663 polymorphism and cancer risk.
| Locus | N* | Allele (T vs. G) | Recessive (TT vs. TG+GG) | Dominant (TG+TT vs. GG) | Homozygote (TT vs. GG) | Heterozygote (TG vs. GG) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) P | I2(%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | OR (95%CI) P | I2 (%) | ||
| Total | 5 | 0.93 (0.84–1.02) 0.102 |
0 | 0.78 (0.54–1.11) 0.163 |
0 | 0.93 (0.84–1.04) 0.193 |
0 | 0.73 (0.51–1.03) 0.071 |
0 | 0.95 (0.85–1.06) 0.350 | 0 |
| Source of controls | |||||||||||
| Population | 3 | 0.93 (0.83–1.04) 0.208 |
0 | 0.79 (0.52–1.20) 0.265 |
0 | 0.94 (0.82–1.07) 0.334 |
0 | 0.74 (0.49–1.11) 0.147 |
0 | 0.96 (0.83–1.10) 0.512 | 0 |
| Hospital | 1 | 1.05 (0.84–1.31) 0.654 |
NA | 0.82 (0.33–2.02) 0.658 |
NA | 1.08 (0.84–1.39) 0.548 |
NA | 0.88 (0.36–2.15) 0.778 |
NA | 1.09 (0.85–1.41) 0.494 | NA |
| Method | |||||||||||
| RFLP | 4 | 0.90 (0.81–1.00) 0.044 |
0 | 0.77 (0.52–1.13) 0.184 |
0 | 0.90 (0.80–1.02) 0.086 |
0 | 0.70 (0.48–1.02) 0.066 |
0 | 0.92 (0.82–1.04) 0.176 | 0 |
| MOLDI-TOF-MS | 1 | 1.05 (0.84–1.31) 0.654 |
NA | 0.82 (0.33–2.02) 0.658 |
NA | 1.08 (0.84–1.39) 0.548 |
NA | 0.88 (0.36–2.15) 0.778 |
NA | 1.09 (0.85–1.41) 0.494 | NA |
| Type of cancer | |||||||||||
| Estrogen-dependent | 2 | 0.96 (0.82–1.13) 0.620 |
23.1 | 0.78 (0.45–1.37) 0.395 |
0 | 0.98 (0.82–1.17) 0.822 |
18.0 | 0.75 (0.43–1.29) 0.296 |
0 | 1.00 (0.83–1.21) 0.991 | 0 |
| Gastrointestinal | 2 | 0.95 (0.83–1.09) 0.443 |
0 | 0.80 (0.47–1.35) 0.400 |
0 | 0.96 (0.82–1.12) 0.576 |
0 | 0.77 (0.46–1.29) 0.325 |
0 | 0.97 (0.83–1.14) 0.729 | 0 |
* Numbers of comparisons. MOLDI-TOF-MS: Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry. RFLP: Restriction Fragment Length Polymorphism. NA: not available.